Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Not Recruiting

Trial ID: NCT00626704

Age - 18 Years-N/A Condition - Soft Tissue Sarcoma Gender - All Accepting Healthy Volunteers - No

Purpose

This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with doxorubicin alone in subjects with previously untreated, locally advanced or metastatic, unresectable soft tissue sarcoma.

Official Title

A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma

Eligibility


Inclusion Criteria:

   - Histologically or cytologically confirmed soft tissue sarcoma

   - Locally advanced, recurrent, or metastatic, unresectable disease

   - Measurable disease according to modified RECIST

   - ECOG performance status of 0 or 1

   - Men or women at least 18 years of age

   - Adequate hematological, renal, hepatic, and coagulation function

Exclusion Criteria:

   - Prior treatment with anthracyclines

   - Uncontrolled cardiovascular disease

View More
View Less

Intervention(s):

drug: AMG 655

other: Placebo

drug: Doxorubicin

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
6507256413

New Trial Alerts

©2024 Stanford Medicine